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Inter-individual, inter-city, and temporal trends of per-and polyfluoroalkyl substances in human milk from Swedish mothers between 1972 and 2016 † Elisabeth Nyberg, * a Raed Awad, b Anders Bignert, a Caroline Ek, a Gerd Sallsten c and Jonathan P. Benskin * b Inter-individual, inter-city, and temporal trends of 19 per-and polyfluoroalkyl substances (PFASs) were investigated in human milk collected in Stockholm and Gothenburg (2007 Gothenburg ( -2015 , Sweden. Overall these data indicate that exposure to some legacy PFASs via breastmilk is declining, presumably as a result of regulation and phase-out initiatives. However, increasing concentrations for other PFASs and a shift in the overall PFAS profile in recent years may pose an ongoing health risk to infants.
Introduction
Per-and polyuoroalkyl substances (PFASs) are a class of over 3000 anthropogenic substances that have been manufactured for over six decades. 1 Owing to their stability and amphipathic properties, PFASs have been used in a wide range of commercial processes and consumer products. 2 Concern over the use of these substances stems mostly from the occurrence of per-uoroalkyl acids (PFAAs; a sub-class of PFAS) in the global environment, including water, 3,4 soils, 5 sediment, 6 wildlife 7 and humans. 8 PFAAs have been linked to a wide range of adverse health effects, including neuro-and immune toxicity, endocrine disruption, and cancer (see review by DeWitt 9 ). Long chain PFAAs are extremely biopersistent, with human blood elimination half-lives on the order of several years. 10 Acknowledgement of the risks associated with long chain PFAAs has led to a number of regulatory and industry phase-out initiatives over the past 17 years. In the year 2000 one of the major global PFAS manufacturers, 3M, began phasing out production of peruoroctanoate (PFOA) and peruorooctane sulfonyl uoride (POSF)-derived products, including per-uorooctane sulfonate (PFOS). 11 North American PFAS manufacturers subsequently volunteered to phase out long-chain PFAAs by 2015, 12, 13 and in 2007, PFOS and POSF were added to Annex B of the International Stockholm Convention on Persistent Organic Pollutants. Nevertheless, production of POSFrelated products continues in some countries under production and use exemptions 14 and recent studies have reported environmental contamination from the increasing use of alternative uorinated substances. 15, 16 Routes of human exposure to PFASs for the general population include food, house dust, air, and drinking water. In infants, occurrence of PFASs is attributed to placental transfer while in the womb, and breastfeeding post-partum. 17 It is estimated that 94% of PFOS intake and 83% of PFOA intake in 6 month-olds is attributable to lactational exposure. 18 Model simulations and empirical data have demonstrated that daily intake through breastfeeding and the resulting internal PFAS levels can be higher in nursing infants than in mothers. 19, 20 Several studies have also shown that maternal PFAS levels decrease during breastfeeding and that PFAS levels in children are correlated to breastfeeding duration, with as much as 2-fold higher mean PFAA concentrations for breastfed infants compared to non-breastfed. 21 Clearly, the effect of PFAS exposure on the health of both mother and baby is of concern. Several studies have reported links between PFAA exposure and perturbation in lipid metabolism [22] [23] [24] and glucose tolerance 24 during pregnancy. Exposure to some PFAAs during early life stages has also been linked to adverse health effects such as reduced birth weight and immune toxicity. [25] [26] [27] Previously, Sundström et al. 28 reported statistically signicant declines in PFOS and PFOA concentrations from 2001-2008 in pooled human milk from Stockholm, Sweden. These trends paralleled time trends observed in human serum from other parts of the world. 18, [29] [30] [31] [32] However, Sundstöm et al. 28 only measured 3 substances -PFOS, PFOA, and PFHxS; numerous other PFASs may exist in breast milk, thereby posing additional risk to infants. Time trends for some PFASs continue to increase in human serum in some parts of the world, including Sweden. 33, 34 Thus, the main objective of the present work was to improve characterization of PFAS contamination in Swedish breastmilk by generating time trends from 1972 to 2016 for an additional 16 PFASs (i.e. a total of 19 PFASs + branched isomers). The second objective was to compare PFAS time trends and inter-individual differences in milk from Stockholm to another city, Gothenburg, in order to assess possible differences in exposure between cities (e.g. due to geographical and/or socioeconomic variation). Finally, PFAS concentrations were used to determine estimated daily intakes (EDIs) for infants which were compared to threshold levels designed to be 'safe' for infant exposure.
Experimental

Sampling
Human milk samples from Stockholm and Gothenburg were mainly collected through the Mothers' Milk Centre at Stockholm South General Hospital and the Institution for Work and Environmental Medicine at Gothenburg University, respectively. Samples were collected between 2 weeks to 3 months aer delivery from healthy native Swedish mothers, who were predominately non-smokers and primiparous ( Table 1 ). There were a total of 20 pooled samples analyzed from Stockholm (Table 1 ). Samples were initially stored at À18 C in plastic bags and bottles. Upon being shipped to the Environmental Specimen Bank at the Swedish Museum of Natural History in Stockholm, samples were thawed, transferred to pre-washed glass bottles with lids covered with aluminum foil, and stored at À20 C prior to analysis. 
Standards and reagents
Chemical analysis
Breast milk aliquots (2 mL each) were extracted according to a previously published method. 28 Briey, aer acidifying with formic acid, each sample was spiked with isotopically labeled internal standards. Samples were then vortexed, fortied with 600 mL of saturated ammonium sulfate, and then vortexed again. Following addition of acetonitrile (7 mL), samples were placed on a mechanical shaker for 30 minutes, aer which they were centrifuged. The top organic layer was transferred into a polypropylene tube and evaporated at 40 C. The extract was then diluted with 300 mL of pure water and vortexed before adding 500 mL of 1 M potassium hydroxide. The tube was vortexed and then supplemented with 7 mL of methyl tert-butyl ether, then placed in a mechanical shaker for 20 minutes followed by centrifugation. The organic layer was subsequently transferred into a clean polypropylene tube. The extracts were evaporated at 40 C and then fortied with 200 mL of buffer (1 : 2 : 1 ammonium acetate : acetonitrile : water). Aer vortexing and centrifugation, the lower layer was transferred to microvial for instrumental analysis.
Instrumental analysis (Table S1, ESI †) was carried out using an ultra performance liquid chromatograph (UPLC) coupled to a Xevo TQ-S triple quadrupole mass spectrometer (Waters) operated in negative ion electrospray ionization, selected reaction monitoring mode. Extracts were chromatographed on a BEH C18 analytical column (2.1 Â 50 mm, 1.7 mm particle size, waters) operated at a ow rate of 0.4 mL min À1 , using a mobile phase composition of 90% water/10% acetonitrile containing 2 mM ammonium acetate (solvent A) and 100% acetonitrile containing 2 mM ammonium acetate (solvent B). The gradient prole is provided in Table S2 , ESI. † A total of two precursor/ product ion transitions were monitored per analyte; one for quantication and the other for qualication (Table S1, ESI †).
Quantitative determination of target compounds was carried out by isotope dilution or an internal standard approach using a linear calibration curve with 1/x weighting. Branched isomers were determined semi-quantitatively using the calibration curve for the linear isomer. The concentration of per-uoropentadecanoate (PFPeDA) was also estimated semiquantitatively using the calibration curve for PFTeDA. With the exception of PFOA and PFOS, primary ions were always used for quantication. For PFOA, the m/z 413/169 ion was used for quantication because of an interference in m/z 413/369. For PFOS, concentrations are reported as the average of m/z 499/80 and 499/99 ions for both branched and linear isomers, as described in Riddell et al. 35 Sum PFOS was then obtained by summing the concentrations of branched and linear PFOS.
Quality control
Laboratory background contamination was monitored by including procedural blanks (2 mL Milli-Q water, n ¼ 4) during the processing of real samples. Method accuracy and precision were assessed using replicate quality control samples, consisting of SRM 1954 (n ¼ 3) and bovine milk analyzed with a low-(0.48-2.03 ng mL À1 ; n ¼ 4), or high-(1.44-6.10 ng mL À1 ; n ¼ 4) spike of PFASs (Table S3 , ESI †). Finally, concentrations of PFOS, PFOA, and PFHxS from 1972-2008 reported in Sundström et al. 28 were compared to data generated in the present work ( Fig. S1 , ESI †).
Data handling
For lower bounds (LB) estimates of sum ( P 19 ) PFAS concentrations, values <LOQ were replaced with '0'. For upper bounds (UB) estimates, concentrations <LOQ were replaced with '0' in cases where a substance was not detected in any sample; in all other cases values <LOQ were replaced with LOQ/2 1/2 . Temporal trend analysis was performed by log-linear regression for the entire monitoring period and for the most recent ten years using the yearly arithmetic mean values. In cases where a nonlinear trend was more representative of the development over time, a 3-point running mean smoother was checked for statistical signicance compared to the regression line using ANOVA. 36 In addition, non-linear trends were investigated using change-point detection, a method that iteratively searches for two log-linear lines with different slopes that explain signicantly more of the total variance than a single regression line tted for the whole monitoring period. 37 Potential outliers were detected using a method described by Hoaglin and Welsch. 38 However, potential outliers are still included in the statistical calculations. The statistical treatment used for trend detection is explained in more detail in Nyberg (2016) . 39 PFASs for which data for more than 70% of the years were below LOQ (i.e. PFPeA, PFPeDA, FHpPA, PFDS, MeFOSAA and EtFOSAA) were excluded from the trend analysis. Principal Component Analysis (PCA) was applied to PFAS proles (i.e. concentration data converted to a percentage of the P PFAS concentration) to study difference in PFAS patterns between Stockholm and Gothenburg (for samples collected 2007-2016) and also over time in Stockholm. This method is described in more detail in Glynn et al. 40 
Results and discussion
Quality control
Blank concentrations were typically below method detection limits for most targets (Tables S5-S7 , ESI †). The exceptions were for PFOA, PFNA, and FOSA, where low concentrations (<12 pg mL À1 ) were consistently observed, which was attributed to the Milli-Q water used to prepare them (and which was not added to real samples). Consequently, blank concentrations were not subtracted from concentrations in real samples. One blank also contained high concentrations of PFHxS, PFOS, PFPeA, PFHxA, PFOA, and PFNA (again arising from the Milli-Q water used to prepare it), but this was deemed anomalous since concentrations in real samples from the same batch, as well as blanks, samples, and QCs from subsequent batches, were all well below these levels. For most substances, method accuracy and precision were good at both fortications levels, with mean (AEstandard error of the mean (SEM)) percent recoveries ranging from 73 AE 1.7% to 129 AE 3.5% and 73 AE 3.9% to 132 AE 4.4% at low-and highspiking levels, respectively. PFHpA, PFBS, and FHpPA displayed lower recoveries at both fortication levels (9-63%), likely due to an absence of exactly-matched, isotopicallylabelled internal standards. Nevertheless, precision remained excellent for these substances and they were detectable at the low fortication level. PFHpA, PFBS, and FHpPA were therefore included in further data processing, albeit with the caveat that concentrations reported here may be underestimated for these targets.
External validation of the method was achieved through (a) comparison of PFAS concentrations measured in SRM 1954 (n ¼ 3) to those reported by Keller et al. 41 (Table S4 , ESI †) and (b) through comparison of PFHxS, PFOS, and PFOA concentrations from 1972-2008 (Stockholm) generated here to concentrations reported previously for these targets in Sundström et al. 28 ( Fig. S1, ESI †) . In general, concentrations reported in the present work were similar or at the lower end of the range reported by Keller et al. 41 (2010) . The exceptions were for PFHxA, which was higher and displayed wider variability than concentrations reported in Keller et al., 41 and PFOA, which was considerably lower in the present work. Given the very low concentrations (i.e. typically $tens of pg mL À1 ) in milk, overall method accuracy and precision was good. Notably, we have reported PFPeA, PFTeDA, PFPeDA, PFHpPA, PFDS, MeFOSAA, and EtFOSAA concentrations in SRM 1954 for the rst time (Table  S4 , ESI †). Finally, a comparison of PFHxS, PFOS, and PFOA concentrations observed here against those in Sundström et al. revealed good correlations (r 2 ¼ 0.72-0.80) with concentrations of PFOS and PFOA distributing approximately evenly above and below the line of y ¼ x (Fig. S1 †) . PFHxS concentrations were mostly situated above this line, indicating slightly lower concentrations in the present work versus Sundström et al. (Fig. S1 †) . Percent differences (i.e. |Sundström-present study|/ Sundström) of 18, 19, and 31% for PFOA, PFOS, and PFHxS, respectively, conrmed that the differences were minor between studies. Overall these data demonstrate good method performance and study intercomparability.
PFAS proles P
19 PFAS concentrations in pooled samples from Stockholm (1972-2016) ranged from 110-470 pg mL À1 for LB estimates (Fig. 1) and from 130-490 pg mL À1 for UB estimates. In Gothenburg (2007-2015) P 19 PFAS concentrations ranged from 110-220 pg mL À1 (LB) and from 130-230 pg mL À1 (UB). A PCA of PFAS proles in Stockholm and Gothenburg from 2007-2015 revealed no signicant difference in patterns (Fig. 2B) , implying the predominant source of PFAS exposure in mothers from both cities is similar.
The highest P 19 PFAS concentration observed among all samples was for the year 1988 from Stockholm (Fig. 1) . Across all years and in both cities, PFOS (sum isomers) and PFOA were consistently the dominant PFASs. The only exception was for PFHxA, which was intermittently detected at concentrations of up to 80 pg mL À1 in 1984 and at concentrations up to 130 pg mL À1 in an individual from 2016. Concentrations of PFOS reported here were within or below the range of average concentrations (46-260 pg mL À1 ; arithmetic means) reported in a worldwide review 42 for 2006-2010. Another review, 43 which included studies from 2008-2015, reported somewhat lower levels (arithmetic means) of PFOS in human milk, more in accordance with concentrations in the present study. PFOA concentrations in this study was also in line with concentrations reported previously (about 40-150 pg mL À1 ). 43 PFAS concentrations in individuals sampled in 2012 from Stockholm and Gothenburg are provided in Fig. 3 . P 19 PFAS concentrations ranged from 83-290 pg mL À1 (LB) and 110-310 pg mL À1 (UB) for Stockholm (n ¼ 20) and 61-290 pg mL À1 (LB) and 90-320 pg mL À1 (UB) for Gothenburg (n ¼ 16). As was the case in pooled samples, the proles in individuals were dominated by PFOS (sum isomers) and PFOA at concentrations of 53 AE 27 and 53 AE 24 pg mL À1 (arithmetic mean of individuals from both cities AE standard deviation), respectively. Notably, FHpPA was observed in 8 samples from Stockholm at concentrations 
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up to 42 pg mL À1 and 1 sample from Gothenburg at a concentration of 15 pg mL À1 . This target was not observed in blanks.
To our knowledge FHpPA has not previously been reported in human milk. This substance (also known as 7 : 3 uorotelomer acid), is a stable transformation production of 8 : 2 uorotelomer alcohol (FTOH), which is incorporated into a wide range of consumer products. FHpPA was previously reported at concentrations up to 3.9 ng mL À1 in serum from ski wax technicians. 44 The short-chain PFOS replacement PFBS also appeared in individuals from Gothenburg at a higher frequency ( Fig. 4 ) whereas a signicant downward trend was observed for Br-and L-FOSA (À3.2 and À4.8% per year respectively, Table 2 , Fig. 4 and S3, ESI †). Concentrations of PFHxS, Br-PFOS and PFDoDA, decreased signicantly between 2007 and 2015 in the milk samples from Gothenburg ( Fig. S2 and S3 , ESI †). Signicant upward-downward change-point trends ( Fig. 4 and S3, ESI †). No trend or change-point was observed for PFHpA and PFDoDA, but for 10 and 11 years (respectively) out of 17 all samples were below LOQ. PFNA and PFDA showed similar increasing trends in pooled blood serum samples from nursing women living in Uppsala. 40 In that study, serum PFHxS increased over the entire monitoring period (including the most recent years). In contrast, PFHxS in milk from the present work showed a signicant decreasing trend from 2004 and onward. In 2012 some of Uppsala's drinking water supply was found to be contaminated with PFASs, most likely originating from re-ghting foams used at a military airport just outside Uppsala. PFHxS was one of the substances found in high levels in the drinking water; consequently, ongoing PFHxS contamination could explain the absence of a decrease in concentrations in that area. 45 In contrast, decreasing trends (1995-2010) for FOSA, PFOA and PFOS concentrations were reported in human serum from Uppsala 40 consistent with our observations in milk and with the phase-out by 3M.
There was a clear shi in PFAS pattern (PFOA, PFNA, PFDA, PFUnDA, PFHxS, Br-PFOS, L-PFOS, PFDS, L-FOSA) over the study period in Stockholm ( Fig. 2A) . Before 1996 the PFAS pattern was dominated by Br-PFOS, L-PFOS and L-FOSA; since then the concentrations of these substances have decreased, while concentrations of PFUnDA, PFDA and PFDS, have increased (samples from 2013-2016). This change in pattern may be due to the large historical production of PFOS and PFOS precursors before 2000, which was followed by ongoing contemporary production of long-chain PFCAs and PFCA precursors. Differences in the environmental fate and/or elimination half-lives of individual PFASs may also inuence trends observed in humans. The centers of gravity for the three time periods were all signicantly different (repeated Hotellings T 2 test, p< the Bonferroni adjusted a value of 0.0167). The shi in PFAS pattern over time in milk from Stockholm is consistent with a shi in pattern reported previously in blood samples from Uppsala 40 over a slightly different time period.
Estimated daily intakes and potential health risks
The upper-and lower-bound PFAS concentrations measured in maternal breast milk were used to determine the estimated daily intake (EDI) of individual and P PFASs via breast milk (Tables S8 and S9 , ESI †). For these calculations an infant body weight of 7 kg and a milk consumption rate of 600 mL per day were used, as described in Kärrman et al. 46 Lower bounds estimates ranged from 7. Whether or not these EDIs represent a signicant health risk for infants is a source of debate. Winkens et al. 47 pointed out 
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that the tolerable daily intake (TDI) for PFOS and PFOA set by EFSA (150 and 1500 ng/kg bw/d, respectively) are up to two orders of magnitude higher than the minimal risk levels (MRL) set by the Agency for Toxic Substances & Disease Registry (30 and 20 ng/kg bw/d, respectively). Notably, none of the EDIs determined here for PFOS or PFOA exceeded these levels, even using upper bounds estimates. However, the aforementioned TDIs and MRLs only consider single substances; safe levels for most of the PFASs measured in the present work have yet to be dened and few data are available on the risks associated with 
Confounding factors
In studies where PFAS concentrations are affected by confounding factors (e.g. age or parity) it is possible to adjust the concentrations for these confounders to lower the variation within the samples. A multiple regression analysis showed no signicant correlations between age (parity was not included in the multiple regression since all mothers from Stockholm in 2012 were primiparous) and concentration for any of the PFAS analyzed in Stockholm 2012. Correspondingly the PFAS concentrations in samples from Gothenburg in 2012 did not show any signicant correlations with either age or parity, with the exception of Br-PFOS which was signicantly negatively correlated with age (p < 0.019). The adjustment of Br-PFOS concentrations with age improved the coefficient of variation (CV) from 77% to 54% (Fig. S4, ESI †) . This is in contrast to the pattern seen for most fat soluble POPs, in which concentrations in milk tend to increase with age. 52 To reduce the inuence of confounding factors the sample denition in the sampling program is narrow, the mothers are of similar age and most of them are primiparous. Thus, the range of the age (Stockholm and Gothenburg) and parity (Gothenburg) were small, which reduces the likelihood of nding signicant correlations with concentration.
Conclusions
While the concentrations of several PFASs have declined in human milk in recent years, others continue to increase, presumably due to ongoing commercial use. These divergent time trends have resulted in a shi in the PFAS prole in human milk over the last 5 years compared to 2000-2012 and pre-2000. As few data are available on the effects of cumulative PFAS exposure, the impact of this 'new' prole on the risks to infant health remain unclear. With this in mind, hazard assessments involving simultaneous exposure to multiple PFASs in relative proportions consistent with those observed in human milk would improve overall risk characterizations, and predictions of the potential health impact of shiing PFAS proles over time.
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